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2Abstract
a-Synuclein is the major constituent of Lewy bodies found in neurons in dementia with Lewy bodies 
(DLB) and might be of diagnostic value as a biomarker for DLB. We hypothesized that, as a 
consequence of increased accumulation of a-synuclein intraneuronally in DLB, the levels of a- 
synuclein in cerebrospinal fluid (CSF) of DLB patients would be lower than in other dementias. Our 
objective was to investigate the CSF levels of a-synuclein in several dementia disorders compared to 
control levels and to investigate the diagnostic value of CSF a-synuclein as a marker to discriminate 
between DLB and other types of dementia. We analysed the levels of a-synuclein in CSF of 40 DLB 
patients, 131 patients with Alzheimer’s disease, 28 patients with vascular dementia, and 39 patients 
with frontotemporal dementia. We did not find any significant differences in CSF a-synuclein levels 
between DLB patients and patients with AD, VaD or FTD. We conclude that in clinically diagnosed 
patients, a-synuclein does not appear to be a useful biomarker for the differentiation between DLB 
and other types of dementia.
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3Introduction
Dementia with Lewy Bodies (DLB) is the second most common type of dementia [1,2,3], accounting 
for 15-20% of cases at autopsy [4]. It is difficult to differentiate between DLB and other dementias 
such as Alzheimer’s disease (AD) using clinical examination [5]. Although specificity has improved 
with the introduction of the consensus guidelines for DLB in 1996 [1,6,7], sensitivity is low [1,3], 
resulting in many misclassified cases. Differentiation from other dementia syndromes is difficult since 
DLB patients can present with symptoms that resemble those of other dementias. Extrapyramidal signs 
and hallucinations, which are characteristic for DLB patients, may also occur in advanced AD. On 
neuropsychological assessment, most DLB patients present with language and memory deficits similar 
to those with AD [8]. In one study, most patients misdiagnosed with DLB had AD pathology at 
autopsy [5]. Accurately diagnosing DLB is important for its pharmacological management. Patient 
with DLB respond well to cholinesterase inhibitors, but are extremely sensitive to the side effects of 
neuroleptic drugs [3,4]. Furthermore, prognosis of patients with DLB may be different, with faster 
deterioration and shorter time between onset of cognitive symptoms and death compared to patients 
with AD [1,5,9].
Analysis of the cerebrospinal fluid (CSF) has been increasingly applied to differentiate the 
various dementia disorders. Especially in AD, a typical CSF pattern is often observed, with increased 
concentrations of total tau protein (t-tau) and phosphorylated tau protein (p-tau) and decreased 
concentrations of the amyloid p42 (Ap42) protein [10,11]. In contrast, there are no generally accepted 
biomarkers to distinguish DLB from other types of dementia. Some studies found equally high CSF t- 
tau concentrations in AD and DLB [12,13]. In most studies, however, CSF t-tau concentrations were 
normal to moderately elevated in DLB [2,8,12,14,15,16,17], with normal concentrations of p-tau 
[18,19]. In contrast, Ap42 concentrations were decreased to a similar degree as in AD [2,8,14,16], 
resulting in a low discriminative value of Ap42 / t-tau analysis to differentiate AD from DLB.
Little research has been done with respect to CSF a-synuclein as a diagnostic marker. a- 
Synuclein is the major constituent of Lewy bodies, which are characteristic cytoplasmic inclusions in
4cortical neurons of DLB patients. Initially a-synuclein was thought to be an intracellular protein, but 
recently it was found in CSF and plasma [20]. Tokuda et al found that patients with Parkinson’s 
disease (PD) had significantly lower a-synuclein levels in their CSF compared to controls [21]. This 
might be explained by accumulation of a-synuclein within affected neurons [21]. We hypothesized 
that levels of a-synuclein in synucleinopathies such as DLB would be decreased in comparison with 
dementias not characterized by a-synuclein inclusions, such as AD, VaD and FTD and with control 
levels. Therefore, we investigated the CSF levels of a-synuclein in these dementia disorders compared 
to control levels, and studied if CSF a-synuclein may serve as a biomarker for the differentiation of 
DLB from other dementias.
5Materials and Methods
Patients
We screened 526 patients of the CSF database of the Alzheimer Centre of the Radboud University 
Nijmegen Medical Centre for inclusion in this study (figure 1). This database consists of clinical data 
and biobank materials of consecutive patients, in whom informed consent for lumbar puncture was 
obtained. We excluded 69 patients because CSF was not available for a-synuclein analysis. Patients 
whose diagnosis was uncertain or with a diagnosis other than DLB, AD, VaD or FTD (e.g. mild 
cognitive impairment) (n=98) were not included either, as were patients with mixed dementia (n=9). In 
total, we included 40 DLB, 131 AD, 39 FTD and 28 VaD patients whose diagnosis was established by 
a multidisciplinary panel, which consisted of a geriatrician, neurologist, neuropsychologist, and -  if 
needed -  an old-age psychiatrist. The panel used the accepted clinical diagnostic criteria, i.e. the 1996 
consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies, the 
NINCDS-ADRDA criteria for AD, the 1998 consensus on clinical diagnostic criteria for 
frontotemporal lobar degeneration, and the NINDS-AIREN criteria for VaD [7,22,23,24]. If possible, 
information on MMSE was obtained and Ap42, p-tau and t-tau were analysed. The panel was aware of 
the CSF results for Ap42, p-tau and t-tau, but not for a-synuclein, when establishing the clinical 
diagnosis.
We compared CSF a-synuclein levels of the dementia patients with those of 57 control 
persons aged >50 years (control group A). Data on Ap42, p-tau and t-tau was not available for this 
group. In order to have reference levels of Ap42, p-tau and t-tau levels to allow comparison of these 
variables, we included another 55 control persons (control group B). Both control groups underwent 
lumbar puncture for various reasons. However, for inclusion, intensive diagnostic investigations was 
not allowed to reveal any neurological disorder. Moreover, the CSF findings of both control groups for 
cell count, glucose, lactate, haemoglobin, bilirubin, total protein and oligoclonal IgG bands had to be 
normal.
A total of 238 patients with dementia and 112 controls were included (figure 1). Patient 
characteristics are listed in table 1. Characteristics of controls are listed in table 2. Mean age (± SD) of 
patients and controls together was 68 (± 10) years and 51% was male. AD patients were more often 
female. FTD patients were significantly younger than patients in the other three dementia groups.
CSF
CSF samples were collected in polypropylene tubes by lumbar puncture and transported to the 
laboratory within 30 minutes after withdrawal. The CSF was centrifuged and aliquots of each sample 
were immediately frozen at - 80°C until analysis. a-Synuclein in CSF was measured using a sandwich 
Elisa system based on a previously described procedure [25]. A disposable flat-bottom microtiterplate 
(Nunc Maxisorp F96, Roskilde, Denmark) was coated with 100 .^l antibody 211 (0.2 ^g/ml in 0.20 M 
carbonate buffer, pH 9.6) overnight at 4°C. A plate washer (BioTek, Beun de Ronde, Abcoude, The 
Netherlands) was used to wash the plate five times with 250 .^l phosphate buffered saline containing
0.05% Tween-20 (PBS washing buffer). All further incubations were performed at 37°C, unless stated 
otherwise, and all measurements were performed in duplicate. 250 .^l of blocking buffer (2.5% gelatin 
in PBS washing buffer) was added and incubated for 2 hours. The plate was subsequently washed five 
times with PBS washing buffer. Next, 100 .^l a-synuclein solution (from 0 to 500 ng/ml diluted in 
PBS) or CSF was added to each well and incubated for 2.5 hours. After washing the plate five times 
with PBS washing buffer, 100 .^l of antibody FL-140, diluted 1:1,000 in blocking buffer, was added 
for 1.5 hours. The plate was washed five times and 100 .^l of the peroxidase labeled goat-anti rabbit 
antibody (dilution 1:5,000 in blocking buffer) was added and incubated for 1 hour. After a final 
washing step 100 .^l of a freshly prepared solution of tetramethyl benzidine (TMB) was applied and 
incubated for 15 minutes in the dark at room temperature. The reaction was stopped with 50 .^l 2 N 
H2SO4 and the absorbance was measured at 450 nm in an ELISA plate reader (Tecan Sunrise, 
Salzburg, Austria). The technicians performing the analyses did not have access to the clinical data.
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7Statistical analysis
Differences in a-synuclein, age, MMSE score, Ap42, p-tau, and t-tau between dementia groups were 
analysed by ANOVA. Levels of a-synuclein, Ap42, p-tau, and t-tau did not follow a normal 
distribution. We used log transformation to analyse these variables. Differences in gender distribution 
among the dementia groups were determined by the chi square test. The associations between a- 
synuclein and age, MMSE score, Ap42, p-tau and t-tau were examined by linear regression. Statistical 
analyses were carried out using SAS, version 8.2.
8Results
The mean CSF level of a-synuclein was not significantly different in the four dementia groups; nor did 
we find a significant difference between the dementia groups and the control group A. We found no 
association of CSF a-synuclein with MMSE score, sex, Aß42 or p-tau among the dementia patients.
The level of a-synuclein decreased with increasing t-tau (B -0.17, p 0.030) and age (B -0.02, p 0.001) 
among the dementia cases (figure 2). Taking these variables into account did not change our initial 
findings about the absence of an association between dementia type and a-synuclein.
In comparison with the univariable associations with a-synuclein, the association with age 
remained stable and significant (B -0.02, p 0.002), while the association with t-tau diminished and lost 
significance (B -0.14, p 0.113) in a linear regression model that included both variables as well as 
dementia type.
In DLB patients, the concentration of Aß42 was significantly lower than in the control group B, 
although still above the cut-off value of 500 pg/ml for normal values. P-tau and t-tau concentrations 
were in the range of normal although significantly increased compared to these controls. For AD 
patients, Aß42 concentration was significantly decreased, while p-tau and t-tau concentrations were 
significantly higher than in the control group B.
9Discussion
We investigated CSF a-synuclein in patients with different types of dementia. To our knowledge, this 
is one of the first studies comparing a-synuclein levels in DLB to other dementias. Since we did not 
observe differences in the CSF levels of a-synuclein between the various clinically diagnosed 
dementia disorders, a-synuclein is not a useful biomarker for the differentiation between DLB, AD, 
FTD or VaD.
What may have accounted for the lack of difference in a-synuclein levels that we observed 
between the different types of dementia, is that a-synucleinopathies, such as DLB, and tauopathies, 
such as AD and part of the FTD cases, may be disorders with considerable overlap, instead of distinct 
entities [26,27]. Neuropathological findings of the various disorders have been reported to be 
overlapping. The presence of Lewy bodies in brains of AD patients was higher than expected [26]. 
More than 60% of cases harboured a-synuclein positive Lewy bodies [28], whereas 87% of brains 
with a neuropathological diagnosis of DLB also met CERAD criteria for definite or probable AD [26]. 
When Iqbal et al divided AD patients into subgroups based on their CSF biomarker profile, a subgroup 
with low Aß42 and only a slight increase in t-tau levels consisted mainly of cases with AD of Lewy 
body type, their CSF biomarker profile comparable to our DLB group [29]. This supports the 
hypothesis of overlapping etiology of a-synucleinopathies and tauopathies. Interestingly, Lewy body 
pathology has also been found in brain tissue of elderly individuals without cognitive impairment 
[26,27].
Another explanation for the lack of difference in a-synuclein levels might be heterogeneity 
within the DLB group. Possibly, there are subgroups within the DLB group. For example, patients 
who display parkinsonism early in the disease could have lower levels of a-synuclein than patients 
whose parkinsonism develops later in the course of the disease. We are uncertain about such 
differences within our DLB group.
Studies addressing the association of a-synuclein in CSF with Parkinson’s disease (PD) report 
contradictory findings. Tokuda et al found lower CSF a-synuclein in PD patients compared to controls
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[21], which led to the assumption that a-synuclein could be used as a marker for a-synucleinopathies. 
However, others did not find significant differences between PD patients and controls [20,30]. In 
Lewy bodies, a-synuclein is aggregated and insoluble [3]. However, under normal conditions a- 
synuclein is a soluble synaptic protein, that can also be found in human CSF and blood plasma of 
healthy humans [3,16,20], and that may be secreted into the CSF by neurons [20,21,31]. Possibly, the 
CSF a-synuclein levels that we and others measured reflect a physiological level of soluble a- 
synuclein, independent of a-synuclein accumulation. The levels of a-synuclein that we measured were 
in the same order of magnitude as found in controls by Tokuda et al, using the same antibodies [21].
We found that age had a weak influence on the levels of a-synuclein, with a-synuclein 
decreasing with age. This is consistent with the study by Tokuda et al [21]. With aging, axonal 
transport of a-synuclein slows down and the amount of soluble a-synuclein decreases [27]. This may 
account for the decreasing levels of a-synuclein found in CSF. Our initial finding that the 
concentration of t-tau increased with decreasing a-synuclein lost significance after correcting for age 
and dementia type.
Our study population is representative for the population seen at a memory clinic and the CSF 
data indicate that our study group was very well comparable to the study groups used by other 
research centres. We observed the typical pattern of decreased Aß42 and increased t-tau /p-tau levels 
in AD patients [8,10]. In DLB we observed comparable decreased Aß42 concentrations, although not 
as low as in AD, and normal to slightly increased t-tau and p-tau concentrations, as has been reported 
before [2,12,14,15,16,17,18,19]. Also, our observations in the VaD and FTD groups are in accord with 
previous studies [8,17,32,33,34,35,36].
Although the clinical diagnoses in our study populations were made according to accepted 
clinical criteria, some misclassification of DLB patients as AD patients probably has occurred. The 
presence of AD pathology in DLB modifies its clinical presentation with a lower rate of visual 
hallucinations and parkinsonism [3]. This contributes to the complicated clinical differentiation 
between these two types of dementia and once more illustrates the urgent need for a discriminative 
biomarker. Our findings suggest that a-synuclein cannot be used as such a diagnostic marker. Future 
studies, e.g. with post-mortem verification of the clinical diagnosis, are warranted to confirm our
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27/13 54/77 24/15 1 8/1 0 0.005J
Age (years) 74.0 ± 8.3 71.7 ± 8.8 66.4 ± 8.6 75.4 ± 8.4 <0.0001
MMSE score 18.9 ± 8.2 
n=7
19.6 ± 3.9 
n=71
20.3 ± 6.1 
n=16
18.5 ± 2.9 
n=6
0.843
Amyloid p42 (pg/ml) 533.0 ± 231.0 
n=33
451.3 ± 147.2 
n=110
702.1 ± 257.8 
n=33
650.1 ± 244.6 
n=24
<0.0001
T-tau (pg/ml) 318.7 ± 161.6 
n=33
716.4 ± 408.9 
n=109
407.3 ± 285.9 
n=33
400.1 ± 543.1 
n=23
<0.0001
P-tau (pg/ml) 56.9 ± 22.2 
n=31
108.7 ± 47.0 
n=109
68.5 ± 34.6 
n=33
52.9 ± 18.6 
n=23
<0.0001
a-Synuclein (ng/ml) 38.0 ± 29.0 37.0 ± 36.1 49.1 ± 41.5 44.3 ± 40.3 0.187
Values are expressed as means ± SD. *, p-value by ANOVA; {, p-value by chi square test.
DLB, dementia with Lewy bodies; AD, Alzheimer disease; FTD, frontotemporal dementia; VaD, vascular 
dementia; MMSE, mini mental state examination (0-30, with higher scores indicating better cognition); t-tau, 
total tau; p-tau, phosphorylated tau.
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Table 2 Clinical characteristics and results o f CSF analysis o f controls
Control group A 
n=57





Age (years) 61.3 i  8.8 61.1 i  8.9
Amyloid ß42 (pg/ml) n.a. 822.9 i  256.3
T-tau (pgm/l) n.a. 212.4 i  81.6
P-tau (pg/ml) n.a. 47.5 i  15.1
a-Synuclein (ng/ml) 30.4 i  19.1 n.a.
Values are expressed as means ± SD.
T-tau, total tau; p-tau, phosphorylated tau; n.a., not available.
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